Here is what the new nasal vaccine is all about.
Bharat Biotech's recombinant nasal vaccine - iNCOVACC - serves as an instrument for primary immunisation against Covid-19 in adults in the 18+ age group and it is meant for restricted use in emergencies only. For the time being, it can be administered only to the unimmunised.
The vaccine uses a modified chimpanzee adenovirus, which cannot replicate in the body to carry the Covid spike protein and thereby induces better immunity.
iNCOVACC is stable at 2-8 degrees Celsius and can be easily stored and distributed. Bharat Biotech has said that it has established large manufacturing capabilities for the vaccine all across India.
iNCOVACC has the dual benefit of enabling faster development of variant-specific vaccines and easy nasal delivery, enabling mass immunisation. It can soon become an important tool in mass vaccination programmes during pandemics and endemics.
According to Bharat Biotech, this nasal vaccine has been specifically formulated to allow intra-nasal delivery through nasal drops. It has been designed and developed to be cost-effective in low and middle-income countries.
Bharat Biotech Unveils Next-Gen Oral Cholera Vaccine To Address Global Health Gaps Bharat Biotech Launches Oral Cholera Vaccine After Successful Phase 3 Trial Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Strangled, Left In Car Trunk: How Harshita Brella Was Killed By Husband AR Rahman, Wife Saira Announce Separation After 29 Years Of Marriage "Rama Krishna Hari": Supriya Sule On Cousin Ajit Pawar's Bitcoin Row Remark World COPD Day 2024: These Lifestyle Changes Can Improve Your Lung Health Adani To Buy PSP Stake To Boost Construction Arm Jailed During Emergency, 93-Year-Old Woman Among Early Voters In Nagpur Track Latest News Live on NDTV.com and get news updates from India and around the world.